Julie Nelson, DO
Family Medicine · Irwin, PANPI 1730325580
Payments from drug & device makers
Across 32 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$167
- Pfizer$91
- Abbott$60
- Johnson & Johnson$49
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
- AbbVie$47
- plus $154 from 8 others
What the payments were for
- Food & beverage$614100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $167 |
| Pfizer | 5 | $91 |
| Abbott | 3 | $60 |
| Johnson & Johnson | 1 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| AbbVie | 3 | $47 |
| AstraZeneca | 2 | $27 |
| Astellas Pharma US Inc | 1 | $21 |
| GSK | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Organon | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$614 in reported general payments places this provider in the 60th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 151 | $100,279 |
| OzempicSemaglutide | 97 | $99,318 |
| XareltoRivaroxaban | 94 | $56,442 |
| TrulicityDulaglutide | 38 | $41,754 |
| JardianceEmpagliflozin | 25 | $28,831 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $28,189 |
| ProliaDenosumab | 14 | $24,400 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $18,411 |
| RybelsusSemaglutide | 14 | $17,843 |
| LinzessLinaclotide | 19 | $17,094 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $9,341 |
| Pantoprazole Sodium | 267 | $6,474 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,460 |
| Atorvastatin Calcium | 671 | $6,318 |
| MyrbetriqMirabegron | 13 | $5,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $167 | $117,161111 claims |
| PfizerEliquis, Abrysvo, Paxlovid | $91 | $107,164189 claims |
| Johnson & JohnsonXarelto | $49 | $56,44294 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $20 | $55,94066 claims |
| Lilly USA, LLCTrulicity | $19 | $41,75438 claims |
| Boehringer IngelheimJardiance | $14 | $28,83125 claims |
| AbbVieLinzess, Synthroid | $47 | $18,83287 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $5,86513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Irwin
- Mary ZakutneyIrwin$393K
- James LimIrwin$210K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.